Displaying drugs 16101 - 16125 of 16219 in total
2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL
Experimental
(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
Experimental
Dapaconazole
Dapaconazole has been used in trials studying the treatment of Tinea Pedis.
Investigational
Ritanserin
Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.
Investigational
Viminol
Experimental
Budipine
Experimental
Picloxydine
Experimental
Xibornol
Experimental
Guanoclor
Experimental
ATX-201
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic
keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their...
Investigational
Matched Description: … The Company determined that the program was not meeting their expected primary and exploratory objectives …
Tapotoclax
Investigational
Matched Iupac: … (1S,3'R,6'R,7'S,8'E,11'S,12'R)-6-chloro-7'-methoxy-11',12'-dimethyl-3,4-dihydro-2H-20'-oxa-13'lambda6 …
CRA_1802
Experimental
NV-18
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and …
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …
2,5-Dimethoxy-4-(n)-propylthiophenethylamine
Experimental
Illicit
4-Bromo-2,5-dimethoxyphenethylamine
Experimental
Illicit
4-Phenylbutylamine
Experimental
Phenethylamine
Experimental
2,5-di-tert-butylhydroquinone
Experimental
(S)-4-Nitrostyrene oxide
Experimental
p-Cumylphenol
Experimental
Displaying drugs 16101 - 16125 of 16219 in total